Objective-Although T-cell-mediated chronic inflammation contributes to atherosclerosis development, the role of a negative regulatory molecule cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in atherosclerosis is poorly understood. We investigated the effects of CTLA-4 overexpression on atherosclerosis in apolipoprotein E-deficient (Apoe 
T -cell-mediated chronic inflammation has been shown to be critically involved in the pathogenesis of atherosclerosis. 1 Although true antigens responsible for driving atherosclerosis remain unclear, differentiation of naïve CD4 + T cells into effector T cells (Teffs) after antigen presentation by antigenpresenting cells (APCs) such as dendritic cells (DCs) has been shown to aggravate atherosclerosis in both humans and mice. 2 Recent experimental studies have shown that forkhead box P3 (Foxp3)-expressing regulatory T cells (Tregs) play an atheroprotective role by dampening Teff responses or modulating lipoprotein metabolism. 3, 4 These findings suggest that the balance between pathogenic Teffs and Tregs may be critical for the prevention of atherosclerotic disease. 5 Activation of T cells requires 2 signals from APCs. The first signal involves interaction of the T-cell receptor with antigenic peptide/major histocompatibility complex ligand. The second signal involves costimulatory molecules on APCs, which boosts or inhibits the first signal depending on the type of costimulation. Costimulatory pathways are crucial not only in modulating naïve and Teff function but also in Treg generation and function and have significant effects on atherosclerosis. 6 The most important costimulatory pathway involves the interaction of B7 ligands CD80 and CD86 on APCs with CD28 on T cells. 7 It has been shown that deficiencies in CD80 and CD86 molecules prevented the development of atherosclerosis in hypercholesterolemic mice by suppressing proatherogenic T helper type 1 (Th1) immune responses, 8 whereas reconstitution with CD80 −/− /CD86 −/− or CD28 −/− bone marrow in hypercholesterolemic mice inhibited Treg development and aggravated atherosclerosis. 3 Thus, the role of CD80/ CD86-CD28 pathway in atherosclerosis may vary depending on modulation of the balance between Teffs and Tregs.
The coinhibitory molecule cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4) is constitutively expressed in CD4 + Foxp3 + Tregs and also in conventional T cells after activation. 9 As a homolog of CD28, CTLA-4 binds to CD80/ CD86 and suppresses T-cell activation. CTLA-4-deficient mice die prematurely from multiorgan inflammation, indicating CTLA-4 as a potent negative regulator of T-cell immune responses. 10 Polymorphism of the CTLA-4 gene is reported to be associated with susceptibility to a variety of autoimmune diseases in humans. 11 Moreover, germline heterozygous mutations in CTLA4 in humans have been shown to result in dysregulation of CD4 + Foxp3 + Tregs and hyperactivation of Teffs and B cells and cause complex immune dysregulation syndrome 12 although heterozygous Ctla4 deficiency in mice shows no autoimmune phenotype. 10 CTLA-4 is important for Treg-mediated suppression of autoimmune diseases 13 and possibly atheroprotection although there is no direct evidence on its role in Treg-mediated atheroprotection. CTLA-4-Ig, a soluble fusion protein consisting of the extracellular CD80/CD86 binding portion of CTLA-4, has been shown to be beneficial for the treatment of autoimmune disease and prevention of organ rejection.
14 CTLA-4-Ig might be beneficial for the prevention of atherosclerotic lesion formation in atherosclerotic mice under specific conditions, such as hyperhomocysteinemia. 15 Moreover, another experimental study demonstrated that CTLA-4-Ig prevented intimal hyperplasia after vascular injury in hypercholesterolemic mice via reduction of Teff responses, and that CTLA-4 blockade using a blocking antibody significantly increased intimal thickening of the injured arteries. 16 Despite these previous studies, the role of CTLA-4 in atherosclerosis has not been fully elucidated.
In the present study, we tested the hypothesis that overexpression of CTLA-4 would inhibit the development of atherosclerosis. To address this issue, we generated CTLA-4 transgenic apolipoprotein E-deficient (CTLA-4-Tg/Apoe −/− ) mice where T cells constitutively express CTLA-4 on the cell surface and intracellularly 17 on background prone to develop atherosclerosis. We examined the effect of CTLA-4 overexpression on the development of atherosclerosis and its underlying mechanisms using these mice. Our findings provide novel evidence that CTLA-4 overexpression suppresses pathogenic immunoinflammatory processes pivotal for atherogenesis through suppression of T-cell activation and downmodulation of DC function and consequently inhibits atherosclerotic plaque formation in the aortic root, identifying CTLA-4 as a possible target for the prevention of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. To investigate the effect of CTLA-4 overexpression in T cells on the development of atherosclerosis, we generated hypercholesterolemic CTLA-4-Tg/Apoe −/− mice by crossing Apoe −/− mice with CTLA-4-Tg mice which express fulllength CTLA-4 under the control of human CD2 promoter. 17 There were no significant differences in body weight, plasma lipid profile, and blood pressure between male or female control Apoe −/− and CTLA-4-Tg/Apoe −/− mice ( Figure 1A ). In parallel with the cross-sectional studies, en face analysis of thoracoabdominal aortas was performed. We found no significant difference in aortic plaque burden between the 2 groups ( Figure 1B) .
Results

Overexpression of CTLA-4 Inhibits
To determine the effects of CTLA-4 overexpression on plaque content, we next performed immunohistochemical studies of atherosclerotic lesions in the aortic sinus. Notably, the atherosclerotic lesions of CTLA-4-Tg/Apoe −/− mice showed a marked 38% reduction in macrophage accumulation and also a significant 42% decrease in CD4 + T-cell infiltration when compared with control mice (Figure 2 ). Relative smooth muscle cell and collagen contents in the aortic sinus plaques were not affected by CTLA-4 overexpression (Figure 2 ). These results suggest that CTLA-4 overexpression reduces plaque inflammation, which may lead to decreased lesion development. 
Effects of CTLA-4 Overexpression on T-Cell Development and Activation
Foxp3
+ Tregs also constitutively expressed intracellular CTLA-4, while significantly higher expression was seen in CTLA-4-Tg/Apoe −/− mice ( Figure 3A) . Consistently, the cell surface expression of CTLA-4 was Figure 3C ). In addition, we performed in vitro proliferation assay of CD4 + T cells labeled with carboxyfluorescein diacetate succinimidyl ester in response to anti-CD3 antibody and observed a significant reduction in CD4 + T-cell proliferation in CTLA-4-Tg/Apoe −/− mice ( Figure 3D ). We also examined apoptosis of CD4 + T cells by staining Annexin V and propidium iodide and found that CTLA-4 overexpression significantly suppressed the early stages of apoptosis in CD4 + T cells ( Figure V in the online-only Data Supplement). Collectively, we suppose that decreased numbers of CD4 + T cells in peripheral LNs and spleen are not because of their impaired development in the thymus or an increase of apoptosis but their reduced proliferative capacity.
To determine whether CTLA-4 overexpression changes T-cell responses and polarization, we examined cytokine secretion from T cells by intracellular cytokine staining. We observed a significant decrease in IFN-γ, interleukin (IL)-4, IL-10, and IL-17 producing CD4 + T cells in the spleen of CTLA-4-Tg/Apoe −/− mice ( Figure 4A ). We further examined cytokine secretion from splenic CD4 + T cells in response to plate-bound anti-CD3 and anti-CD28 antibodies using ELISA. Splenic lymphocytes from CTLA-4-Tg/Apoe −/− mice secreted less proatherogenic Th1 cytokine IFN-γ and immunosuppressive Treg-associated cytokine IL-10 than those from controls, whereas no differences in Th2 cytokine IL-4 and Th17 cytokine IL-17 were observed ( Figure 4B ). To determine whether overexpression of CTLA-4 suppresses T-cell activation in vivo, we examined T-cell activation markers of peripheral LNs and spleen and found a marked decrease in the proportion of CD44 
Overexpression of CTLA-4 Inhibits Maturation of DCs and Suppresses T-Cell Activation
DCs express costimulatory molecules such as CD80 and CD86 that bind to receptors on the T cells simultaneously with antigen recognition, leading to T-cell activation. 7 To determine whether the CD80 and CD86 expression on DCs is influenced by hypercholesterolemic conditions, we compared their expression levels between wild-type and age-matched or aged Apoe −/− mice. CD11c + DCs from hypercholesterolemic Apoe −/− mice expressed higher levels of CD80 but not of CD86 than those from normocholesterolemic mice (data not shown), which is consistent with a previous report using hypercholesterolemic low-density lipoprotein receptor-deficient mice fed a high-cholesterol diet. 19 These results suggest that the upregulation of CD80 expression on DCs may be critical for augmentation of proatherogenic T-cell immune responses and atherosclerotic plaque formation under hypercholesterolemic conditions. Downregulation of CD80 and CD86 expression on DCs by CTLA-4 is reported to be a key mechanism for Tregmediated suppression. 13 Therefore, we examined CD80 and CD86 expression on splenic CD11c + major histocompatibility complex + DCs from Apoe −/− or CTLA-4-Tg/Apoe −/− mice and found a significant decrease in their expression in CTLA-4-Tg/Apoe −/− mice ( Figure 5A ), revealing suppressed maturation of DCs by binding of CTLA-4 to CD80/CD86 on their surface. The CD40 expression on splenic CD11c + DCs was not affected by CTLA-4 overexpression (data not shown). We examined cytokine production in splenic CD11c + DCs by quantitative reverse transcription polymerase chain reaction, and found that there were no significant differences in the mRNA expression of anti-inflammatory cytokine IL-10 and proinflammatory cytokines IL-12p35 or IL-12p40 between Apoe 
Foxp3
+ Tregs is considered to be important for Treg-mediated suppression. 13 Therefore, it can be speculated that CD4 
CTLA-4-Mediated Suppression of Atherosclerosis in the Aortic Root Is Associated With Reduced Aortic Immunoinflammatory Responses
To reveal the mechanisms of reduced atherosclerotic lesions and macrophage or CD4 + T-cell infiltration in the aortic root, we examined mRNA expression of several immune cell markers in atherosclerotic aortas by quantitative reverse transcription polymerase chain reaction. We found that proatherogenic cytokine IFN-γ, T-cell marker CD4, and costimulatory molecule CD80 were markedly reduced in CTLA-4-Tg/Apoe −/− mice compared with control mice ( Figure Taken together, these data indicate that CTLA-4 overexpression inhibits intraplaque Teff accumulation without affecting the proportion of Foxp3 + Tregs in the aortic root plaques, which may lead to reduced plaque inflammation and lesion development.
Discussion
It is now well-established that chronic immunoinflammatory responses play a central role in atherogenesis.
1 Although compelling experimental data suggest that regulation of T-cellmediated proatherogenic immune responses may potentially be an attractive therapeutic approach to prevent atherosclerosis, there are no therapeutic methods available to specifically intervene the inflammation or immune system in clinics. In the present study, we established hypercholesterolemic CTLA-4-Tg mice and demonstrated that overexpression of CTLA-4 prevents atherosclerosis in the aortic root by suppressing proatherogenic immune responses. We found that this reduction of atherosclerosis is associated with decreased numbers of CD4 + Teffs and decreased expression of costimulatory molecules CD80 and CD86 on CD11c + DCs. Consistent with in vivo findings, we also found that CD4 + T cells from CTLA-4-Tg/Apoe −/− mice show decreased proliferative capacity and proinflammatory cytokine production, downregulated CD80 expression on CD11c + DCs, and suppressed the proliferation of other T cells in vitro, suggesting that CTLA-4 regulates proatherogenic immune responses through cell intrinsic and extrinsic pathways. Thus, we identified CTLA-4 as an attractive therapeutic target for atherosclerosis ( Figure XI in the online-only Data Supplement).
T-cell-mediated immune responses have been shown to substantially contribute to driving or suppressing inflammation involved in the pathogenesis of atherosclerosis, depending on T-cell subsets. 2 
Foxp3
+ Tregs in CTLA-4-Tg/Apoe −/− mice when compared with control mice, despite modest upregulation of their suppressive capacity. Given that generation and homeostasis of Tregs depend on interactions between CD80/CD86 and CD28, 7 it is likely that decreased numbers of CD4 Despite the importance of CTLA-4 as a negative regulator of T-cell activation, its mechanism of action is still debated. Several possible mechanisms including cell intrinsic or cell extrinsic pathways have been reported for how CTLA-4 on Teffs and Tregs negatively controls immune responses. 9 As a cell intrinsic mechanism, costimulatory ligands such as CD80 and CD86 expressed on DCs bind to CTLA-4 on T cells that receive a negative signal through its cytoplasmic tail, leading to inhibition of T-cell receptor signaling and prevention of subsequent T-cell activation.
14 In our study, in vitro proliferation assay of carboxyfluorescein diacetate succinimidyl ester-labeled CD4 + T cells revealed a significant reduction in CD4 + T-cell proliferation on anti-CD3 antibody stimulation in CTLA-4-Tg/Apoe −/− mice, indicating the involvement of the cell intrinsic mechanism for CTLA-4-mediated atheroprotection.
An experimental study performing bone marrow transplantation of a mixture of wild-type and Ctla4
-/-cells revealed that cell extrinsic pathways are critical for CTLA-4-mediated immune regulation in vivo. 27 CD4 + Foxp3 + Tregs are known to constitutively express CTLA-4, which is essential for their suppressive function in vitro and in vivo. As an important cell extrinsic mechanism for CTLA-4-mediated immune suppression, CD4 + Foxp3 + Tregs suppress immune responses partly by CTLA-4-dependent downregulation of CD80 and CD86 on APCs. 13 Recently, CTLA-4 has been shown to remove its ligands CD80/CD86 from APCs by a process of transendocytosis. 28 Given that CTLA-4 has much higher affinity than CD28 for their common ligands CD80 and CD86, it outcompetes and deprives CD28 signal from responder T cells. 29 Therefore, it is highly possible that CTLA-4 can act as an inhibitor for CD80/CD86-CD28 pathway, which may contribute to the inhibition of proatherogenic T-cell immune responses and atherosclerosis development in the present study. It is reported that CTLA-4 may negatively regulate immune responses by ligating CD80 and CD86 and upregulating indoleamine 2,3-dioxygenase in DCs, resulting in decreased tryptophan and inhibition of T-cell proliferation. 30 However, we think this unlikely in the present study because quantitative reverse transcription polymerase chain reaction analysis of mRNA expression of indoleamine 2,3-dioxygenase in splenic CD11c + DCs demonstrated no difference between CTLA-4-Tg/Apoe −/− and control mice (data not shown).
Our findings might have important clinical relevance. The immunoregulatory effect of a soluble fusion protein CTLA-4-Ig may involve blockade of CD80/CD86-CD28 pathway, which is one of the cell extrinsic mechanisms for CTLA-4-mediated immune regulation. Based on previous studies 15, 16 and our data, we expect that CTLA-4 may be a possible therapeutic target for atherosclerotic disease. Given that CTLA-4-Ig has been already clinically used and has been shown to be effective for treating patients with rheumatoid arthritis who have high incidence of atherosclerotic cardiovascular disease, our findings imply that an immunomodulatory approach such as costimulatory blockade by CTLA-4-Ig may be effective for treating atherosclerosis and rheumatoid arthritis. It is intriguing to test this hypothesis and we hope that future clinical studies will address this issue. Ipilimumab, a fully human monoclonal antibody that blocks CTLA-4, has antitumor capacity and has been demonstrated to be effective for treating metastatic melanoma in combination with other anticancer agents. 31 Our data and a previous report 16 suggest that inhibition of CTLA-4 function may promote atherosclerosis by stimulating proatherogenic Teff immune responses. Therefore, it will be important to consider the potential risk of accelerated atherosclerosis by CTLA-4 blockade therapy.
In summary, we demonstrate that coinhibitory molecule CTLA-4 regulates proatherogenic immune responses through cell intrinsic and extrinsic mechanisms. Our study establishes CTLA-4 as an attractive therapeutic target for preventing atherosclerotic disease. Although careful management is required for application in clinical settings because of general immunosuppression by targeting the coinhibitory pathways, our data suggest that therapeutic intervention aimed at enhancing CTLA-4 function may be a potentially valuable approach for preventing atherosclerosis.
